Domestic antihypertensive top 10 drugs exposure, the two major domestic brands on the list.

Pharmaceutical Network Industry Dynamics In recent years, with China's aging population, changes in living habits, etc. leading to the increasing number of patients with chronic diseases.
and high blood pressure diseases are gradually beginning to become the highest prevalence of various chronic diseases.
growing population of disease, the demand for drugs has also directly contributed to the growing market for antihypertensive drugs.
According to the data, the market size of China's urban retail pharmacy terminal antihypertensive drug market exceeded 14 billion yuan in 2019, up 3.7% year-on-year, according to the data.
, the total sales of the top 10 products of antihypertensive drugs have exceeded 8.5 billion yuan, benzene sulfonate chlorate tablets, benzodiazepine sein flat tablets, nitrobenzene flat control release tablets annual sales of more than 1 billion yuan, sulfonamide chloride flat tablets is the first time to exceed 2 billion yuan.
at present, from the overall point of view, the domestic antihypertensive drug market as a whole is more scattered, is still the leading foreign-funded enterprises.
but it is worth mentioning that in 2019 in the retail drugstore antihypertensive market occupied mainly by the original research enterprises, there are two domestic brands into the retail pharmacy sales of the top 10, respectively, Shi Huida's benzodiazepine chloroammonia chlorine flat tablets and Qingdao Huanghai Pharmaceutical nitrobenzene flat release tablets.
Shi Huida: Phenyl sulfonate chloro-chlorosulfonate chlorocyclosulphate chlorine flat tablets are a new generation of long-acting dihydroquine class antihypertensive drugs.
at the end of the 20th century, Shihuida Pharmaceuticals' innovative original research drug, chlorocyclosulphate chlorpyrifos, was approved for listing by cFDA.
"Shi Huida" is China's first case of hand-splitting optical pure drugs, included in the Chinese Academy of Sciences "95" "11th Five-Year Plan" "12th Five-Year" major scientific research projects, by the National Development and Reform Commission as "high-tech industrialization demonstration projects.
although there are a number of imitations listed, but ShiHuida Pharmaceuticals' original research drug benzene sulfonate chlorocyclosulphate chlorine flat tablet "Shi Huida" still with a 77.3% share, and 4.34% growth rate leading the market. Qingdao Huanghai Pharmaceutical
: nitrobenzene flat release tablet nitrobenzene is the early listed calcium ion channel antagonists (CCB class) drugs, is one of the representative drugs of the ground level drugs, because of the rapid pressure reduction, strong effect, blood pressure lowering at the same time also alleviate angina, delay atherosclerosis and other roles, is widely used in clinical.
and Qingdao Huanghai Pharmaceuticalproduction production of The Fuda (Nitrobenzene flat release tablet (II),) ), indications for the treatment of hypertension, angina.
in 2019 in China's urban retail pharmacy terminal antihypertensive drug market, Qingdao Huanghai Pharmaceutical's nitrobenzene flat release tablets accounted for 57.5% of the market share.
in general, the incidence of hypertension in China is increasing year by year, hypertension drug market will be further increased.
at present, the proportion of people with high blood pressure who are informed and drug-interventionist is relatively small, and the market for hypertension medication will open up further as medical levels and people's medical awareness continue to improve.
of course, the market prospects are broad, the industry is expected to become more competitive.
.